28-12-2023, 08:46 AM
It will be interesting how this pans out. Apparently the pharmaceutical companies aren't prioritising antibiotic development because the returns are much lower than for other drugs such as for cancer, alzheimers and inflammatory conditions. Antibiotics also present a reducing return on development costs due to resistance occurring so quickly.